C. Ola Landgren

临床试验

计划入组 200 人 · 首次发布于 2021 年 6 月 23 日

尚未招募

NCT06964633

The Ku Ola Project: Enhancing Health Promotion Among Native Hawaiian Men.

计划入组 600 人 · 首次发布于 2025 年 5 月 9 日

已完成

NCT01898754

Oligonucleotide Ligation Assay (OLA) Resistance Study

计划入组 991 人 · 首次发布于 2013 年 7 月 12 日

药物

查看全部 2152 →

C 135LS/C 144LS

Small Molecule

Experimental

Lanatoside C

C₄₉H₇₆O₂₀

Small Molecule

Approved

Vitamin C(Ascor, Citranatal B-calm Kit, Concept Ob, Ferralet 90, Hematogen, Infuvite, Infuvite Pediatric, Moviprep, Mvc-fluoride, Mvi Pediatric, Natafort, Plenvu, Pregvit, Vitafol-one)

相关疾病：Common Cold, Deficiency, Vitamin A，另有 10 项

C₆H₈O₆

机构

查看全部 3120 →

Carlsson, Per-Ola

Sweden

C & C Oxygen Company

United States

Buchanan C Michael

United States

资讯

查看全部 2499 →

2年前

FDA Panel Supports MRD as Endpoint for Accelerated Approval in Multiple Myeloma

去年

FDA Committee Greenlights Minimal Residual Disease Endpoint for Accelerated Multiple Myeloma Drug Approvals

去年

临床试验

Outpatient Liquid Aspirin (OLA)

The Ku Ola Project: Enhancing Health Promotion Among Native Hawaiian Men.

Oligonucleotide Ligation Assay (OLA) Resistance Study

药物

C 135LS/C 144LS

Lanatoside C

Vitamin C(Ascor, Citranatal B-calm Kit, Concept Ob, Ferralet 90, Hematogen, Infuvite, Infuvite Pediatric, Moviprep, Mvc-fluoride, Mvi Pediatric, Natafort, Plenvu, Pregvit, Vitafol-one)

机构

Carlsson, Per-Ola

C & C Oxygen Company

Buchanan C Michael

资讯

FDA Panel Supports MRD as Endpoint for Accelerated Approval in Multiple Myeloma

FDA Committee Greenlights Minimal Residual Disease Endpoint for Accelerated Multiple Myeloma Drug Approvals

FDA's Approval of MRD as End Point Transforms Multiple Myeloma Research and Treatment